Home

BIO Digital

Speakers & Presenters

Meet the experts speaking on our world-class education program.

2020 BIO Digital Thought Leaders

Featured Speakers

Sharon Chan, MBA, MPH, D. Phil

HEAD JLABS @ SHANGHAI, JOHNSON & JOHNSON INNOVATION

Sharon Chan is the Head of JLABS @ Shanghai. In this role, Sharon is responsible for setting the strategic direction and overseeing all operational…

Paul Stoffels, MD

VICE CHAIRMAN OF THE EXECUTIVE COMMITTEE AND CHIEF SCIENTIFIC OFFICER, JOHNSON & JOHNSON

Paul Stoffels is a visionary leader who inspires and drives transformational innovation to bring years of life and quality of life to millions of…

Anthony Fauci, MD

DIRECTOR, NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, NATIONAL INSTITUTES OF HEALTH

ANTHONY S. FAUCI, MD is director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health,…

All Speakers

By Count | Alphabetical

Show All

By Count | Alphabetical

Show All

By Count | Alphabetical

Show All

Company Type

Show All

Main Therapeutic Focus

Show All

Development Phase of Primary Product

Show All

Search Speakers

Speaker Name

Country

Company

All Speakers

Filter by letter

Federico Mingozzi, PhD

CHIEF SCIENTIFIC OFFICER, SPARK THERAPEUTICS

The Next Generation of Medicine: Cell Therapies, Gene Therapies and Beyond

United States

Sandy Macrae, PhD

CEO, SANGAMO THERAPEUTICS

Genomic medicine and bioethics – Ushering in a new era of responsible healthcare

San Francisco, California, United States

Marinna Madrid

CO-FOUNDER, CELLINO

Cellino

Cambridge, Massachusetts, United States

Carmen Maher

SENIOR DIRECTOR MEDICAL REGULATORY/SENIOR REGULATORY ADVISOR, JPEO CBRND AND DEFENSE THREAT REDUCTION AGENCY / JOINT SCIENCE AND TECHNOLOGY OFFICE (DTRA / JSTO)

Back to “Normal?”: The Department of Defense’s Role in COVID-19 Screening and Diagnostics

Fort Detrick, Maryland, United States

Stanley Maloy, PhD

ASSOCIATE VICE PRESIDENT FOR INNOVATION, SAN DIEGO STATE UNIVERSITY

Diversity and Inclusion in the Bio-innovation Ecosystem

San Diego, California, United States

Mathai Mammen, MD, PhD

GLOBAL HEAD, RESEARCH & DEVELOPMENT, JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON

Fireside Chat with Mathai Mammen, MD, PhD, Global Head, Research and Development, Janssen Pharmaceutical Companies of Johnson & Johnson

Doug Manion, MD

CEO, KLEO PHARMACEUTICALS, INC.

Getting to the Tumor: Beyond the First Generation of Tumor Targeting Technologies

Natural Killer (NK) Cells: Pushing the Next Wave of Immuno-oncology Therapies

New Haven, Connecticut, United States

Husseini Manji, FRCP (C), MD

GLOBAL THERAPEUTIC AREA HEAD, NEUROSCIENCE, JOHNSON & JOHNSON

How COVID-19 Has Impacted the Global Psyche

Titusville, New Jersey, United States

Upendra Marathi

PRESIDENT & CEO, 7 HILLS PHARMA

7 Hills Pharma

Houston, Texas, United States

Heidi Marchand, PharmD, RPh

GLOBAL HEAD, REGULATORY POLICY AND INTELLIGENCE, GILEAD SCIENCES

Race Against the Clock: Bringing New Cell and Gene Therapies to Market

United States

Magdalena Marciniak

BUSINESS ALLIANCE DIRECTOR, RYVU THERAPEUTICS

Ryvu Therapeutics

Gary Margolis

CEO, NOTOGEN, INC.

Notogen, Inc.

Toronto, Ontario, Canada

Jeff Margolis

CHAIRMAN, WELLTOK

Asymmetrical Challenges of Innovation

Brad Margus

CHIEF EXECUTIVE OFFICER, CEREVANCE

Battle of the Brains: Rethinking Neurodegenerative Disease Treatment

Boston, Massachusetts, United States

John Markels, PhD

PRESIDENT, MERCK VACCINES, MERCK & CO.

A Way Forward: Winning the War on COVID through Vaccines

North Wales, Pennsylvania, United States

Peter Marks, MD, PhD

DIRECTOR, CENTERS FOR BIOLOGICS EVALUATION & RESEARCH, US FOOD & DRUG ADMINISTRATION

A Way Forward: Winning the War on COVID through Vaccines

Realizing the Promise of Gene Therapies for Patients Around the World: A Year of Progress

FDA Town Hall

Silver Spring, Maryland, United States

Michael Markus, PhD

CEO, HGE HEALTH

Digital Health in Respiratory Care – The Next Frontier

Philadelphia, Pennsylvania, United States

Andy Marshall, PhD

CHIEF EDITOR, NATURE BIOTECHNOLOGY

Nature Biotechnology and Scientific American WORLDVIEW: Whiplash! How COVID-19 Will Radically Change Biomedical R&D Across the Globe

United States

Brian Martin, BS, MS

HEAD OF AI IN R&D INFORMATION RESEARCH, SENIOR PRINCIPAL DATA SCIENTIST, ABBVIE

Demystifying buzzwords – How AI and machine learning are being used NOW in the life sciences

Lake Forest, Illinois, United States

Linda Masat

V.P. BUSINESS DEVELOPMENT, TRIANNI INC.

Trianni, Inc

San Francisco, CA, California, United States

Carmela Mascio

PRESIDENT & CO-FOUNDER, LIVONYX INC.

LivOnyx Inc.

Allston, Massachusetts, United States

Neal Masia, PhD

CEO, HEALTH CAPITAL GROUP

Financing Transformative Therapies: Cross-sector perspective on value, payment and real-world evidence

New York, New York, United States

Cristina Masseria, MSc, PhD

VP PATIENT HEALTH & IMPACT, VACCINES, PFIZER

Financing Transformative Therapies: Cross-sector perspective on value, payment and real-world evidence

Gary Mathias

CEO, THETIS PHARMACEUTICALS

Thetis Pharmaceuticals

Branford, Connecticut, United States

Kazuhiro Matsuda, MD, PhD

PRESIDENT, M BIO TECHNOLOGY INC.

M Bio Technology Inc.

Tokyo, Japan

Osamu Matsuzaki

BOARD DIRECTOR, SENIOR EXECUTIVE OFFICER, HEAD OF R&D AND BD, ASAHI KASEI PHARMA CORPORATION

Asahi Kasei Pharma Corporation

Tokyo, Japan

Martin Matthews

DIRECTOR OF GOVERNMENT AFFAIRS, MERCK & CO.

Bioscience Professional Toolkit - How to successfully transition to a post-academic career

North Wales, Pennsylvania, United States

Allison Matusick

GLOBAL ACCOUNTS DIRECTOR, CORNING INCORPORATED

Corning Incorporated

Corning, New York, United States

Jeff May

VICE PRESIDENT, GLOBAL PUBLIC POLICY, MERCK

International Trade in the Times of COVID-19

Kenilworth, New Jersey, United States

Kiran Mazumdar Shaw

CHAIRPERSON & MANAGING DIRECTOR, BIOCON LIMITED

The Lure of Universal Healthcare ! What India is doing in Healthcare

Bangalore, India

James McArthur, BSc, D. Phil

FOUNDER & PRESIDENT, R&D, CYDAN

Drug repurposing for new treatments of rare diseases: the academic, biotech, and investor perspective

Cambridge, Massachusetts, United States

Andrew McCandlish

HEAD OF US BUSINESS DEVELOPMENT, PH PHARMA

Getting a seat at the table: how can new small companies enter the oncology space?

South San Francisco, California, United States

Corey McCann, MD, PhD

FOUNDER & CEO, PEAR THERAPEUTICS

Asymmetrical Challenges of Innovation

Boston, Massachusetts, United States

Reenie McCarthy

CHIEF EXECUTIVE OFFICER, STEALTH BIOTHERAPEUTICS

Mitochondria: How the Relic from Biology Class Could be the Next Powerhouse for Biopharmaceutical Innovation

Newtown, Massachusetts, United States

Mark McClellan, MD

DIRECTOR, DUKE UNIVERSITY MARGOLIS CENTER FOR HEALTH POLICY

A Way Forward: Winning the War on COVID through Vaccines

Washington, United States

Barbara McClung

CHIEF LEGAL OFFICER AND CORPORATE SECRETARY, CARIBOU BIOSCIENCES, INC.

GETTING IT 'JUST RIGHT': The Goldilocks Strategy for Effective and Efficient IP Due Diligence Processes

GETTING TO YES: Negotiating IP Terms in Contracts

Berkeley, California, United States

Joshua McClure, MBA

CEO, MAXWELL BIOSCIENCES

MaxWell Biosciences

Austin , Texas, United States

Mark McCord-Amasis, MBA, MSc

VICE PRESIDENT, REAL ESTATE & FACILITIES, SEATTLE GENETICS

Identify and Mitigate: “Bet Your Company” Risks

BOTHELL, Washington, United States

Andrew McKee, MD

CEO AND PRESIDENT, HEADLAND STRATEGY GROUP

How an Innovation Ecosystem Enables Growth During Times of Crisis and Beyond

Headland Strategy Group

San Francisco, California, United States

Matt McLoughlin

VP OF COMPLIANCE & CATEGORIES, SCIENTIST.COM

Scientist.com

Manchester, United Kingdom

Matthew McMahon

FEDERAL PROGRAM STAFF, NIH SEED

The Key Role of NIH in the Product Development Pipeline

United States

Gianna McMillan

PROGRAM ADMINISTRATOR, BIOETHICS INSTITUTE AT LOYOLA MARYMOUNT UNIVERSITY

Including the Patient Voice to Advance Diversity and Support Clear Communications

United States

Michelle McMurry-Heath, MD, PhD

PRESIDENT AND CHIEF EXECUTIVE OFFICER, BIOTECHNOLOGY INNOVATION ORGANIZATION

Biotech’s Finest Hour

Science on the Front Lines & on the Front Page

A Way Forward: Winning the War on COVID through Vaccines

Washington, United States

Jenn McNary

PATIENT ADVOCATE, J. MCNARY CONSULTING

Get Engaged! How to Talk to ICER and Anyone Else Forming Opinions About Your Care Coverage

Boston, Massachusetts, United States

David Mead, PhD

CEO, VARIGEN BIOSCIENCES

Varigen Biosciences

Madison, Wisconsin, United States

Ravi Mehrota, PhD

, 5POINT0

Patents in the Time of Covid-19: Innovation and Access to Medicine now and for the future

Julien Meissonnier

VP & CSO, CATALENT

Technology Integrators in Cell and Gene Therapy: Powering Innovation

BioProcess Insider Interviews

Joseph (Joe) Melnik

PARTNER, JONES DAY

GETTING TO YES: Negotiating IP Terms in Contracts

Palo Alto, California, United States

Hanne Mette Kristensen

CEO, THE LIFE SCIENCE CLUSTER

The Nordics

Oslo, Norway

Philipp Mews, PhD

COFOUNDER , EPIVARIO INC.

PTSD treatment limitations and novel pharmacotherapy approaches to transform standard of care

New York, New York, United States

Annastasiah Mudiwa Mhaka, PhD

CO-FOUNDER, CONVENOR, FORMER PRESIDENT; FOUNDER, ALLIANCE FOR ARTIFICIAL INTELLIGENCE IN HEALTHCARE; MAWAMBO LIFESCIENCES

Can AI Prevent Epidemics?

Zhuqi Miao

INTERIM MANAGER, INSTITUTE OF PREDICTIVE MEDICINE , OKLAHOMA STATE UNIVERSITY—CENTER FOR HEALTH SYSTEMS INNOVATION (CHSI)

Oklahoma State University—Center for Health Systems Innovation (CHSI)

Stillwater, Oklahoma, United States

Michael Miller, PhD

CEO, PROTERIXBIO

Digital Health in Respiratory Care – The Next Frontier

Billerica, Massachusetts, United States

Debra Miller

CHIEF EXECUTIVE OFFICER & FOUNDER, CUREDUCHENNE

Realizing the Promise of Gene Therapies for Patients Around the World: A Year of Progress

Newport Beach, California, United States

Steve Miller, MD

EVP & CHIEF CLINICAL OFFICER, CIGNA CORPORATION

Rare Disease Therapies are No Longer Rare: Can the US Healthcare Reimbursement System Handle Chronic Treatments for Orphan Diseases

Financing Transformative Therapies: Cross-sector perspective on value, payment and real-world evidence

Missouri, United States

Jennifer Miller, PhD

ASSISTANT PROFESSOR, FOUNDER, YALE SCHOOL OF MEDICINE, BIOETHICS INTERNATIONAL

Genomic medicine and bioethics – Ushering in a new era of responsible healthcare

Emily Milligan

EXECUTIVE DIRECTOR, BARTH SYNDROME FOUNDATION

Mitochondria: How the Relic from Biology Class Could be the Next Powerhouse for Biopharmaceutical Innovation

Elizabeth Mily

EXECUTIVE VICE PRESIDENT, STRATEGY & BUSINESS DEVELOPMENT , BRISTOL MYERS SQUIBB

How to Get Acquired: What Companies Look for When in Acquisition Mode

Bristol Myers Squibb

Princeton , New Jersey, United States

Frank Minella

FOUNDER & CEO, PAINQX

PainQx

Philadelphia, Pennsylvania, United States

Brigitta Miranda-Freer

EXECUTIVE DIRECTOR, MONTANA WORLD TRADE CENTER

Montana - Global Innovation Hub

Missoula, Montana, United States

Tim Mitchell

CEO, SAREUM

Sareum Holdings plc

Cambridge, United Kingdom

Kenneth Moch

ADVISOR, COGNITION THERAPEUTICS AND CHIMERIX

Bioethics Through the Lens of a Pandemic

United States

James Moe

PRESIDENT AND CEO , OLIGOMERIX, INC.

Oligomerix, Inc.

Bronx, New York, United States

Amanda Moore

CEO , ANGELMAN SYNDROME FOUNDATION

Rare Disease Therapies are No Longer Rare: Can the US Healthcare Reimbursement System Handle Chronic Treatments for Orphan Diseases

Indianapolis, Indiana, United States

K. Scott Moorefield

CHIEF BUSINESS OFFICER, BOUNDLESS BIO INC.

Boundless Bio Inc.

La Jolla , California, United States

Susan Moran, MD, MSc

CHIEF MEDICAL OFFICER, QED THERAPEUTICS / BRIDGEBIO

Looking for the Next Targeted Oncology Blockbuster

San Francisco, California, United States

Yusuke Moritoh

BIOLOGY TEAM1 HEAD, SCOHIA PHARMA, INC.

SCOHIA PHARMA, Inc.

Kanagawa, Japan

James Morrissey, PhD

PROFESSOR OF BIOLOGICAL CHEMISTRY & INTERNAL MEDICINE, UNIVERSITY OF MICHIGAN MEDICAL SCHOOL

The human biologic response to vascular injury: a complex interaction among inflammation (innate and adaptive), coagulation and acuity of the injurious stimulus

Lonnie Moulder

FOUNDING PARTNER, TELLUS BIOVENTURES, LLC

How to Get Acquired: What Companies Look for When in Acquisition Mode

United States

Ryan Muldoon

CEO, PREP BIOPHARM

PrEP Biopharm

London, United Kingdom

Emily Mullin

STAFF WRITER, ONEZERO

Mitochondria: How the Relic from Biology Class Could be the Next Powerhouse for Biopharmaceutical Innovation

Rockville, Maryland, United States

Theresa Mulloy, BA

PROGRAM MANAGER INTERNATIONAL BUSINESS PROMOTION & INWARD INVESTMENT, PUGLIA SVILUPPO S.P.A.

Puglia Sviluppo S.p.A.

Modugno, Italy

Carolyn Mulroney

HEMATOLOGIST/MEDICAL ONCOLOGIST, ASSOCIATE PROFESSOR OF MEDICINE, UC SAN DIEGO HEALTH, UNIVERSITY OF CALIFORNIA SAN DIEGO

Transplant 2.0: Driving Forward Innovation for Patients with Blood Cancer

La Jolla, CA, California, United States

Ann Murray

DIRECTOR, BUSINESS DEVELOPMENT, CHARLES RIVER LABORATORIES

Charles River Laboratories

Wilmington , Massachusetts, United States

Anant Murthy, PhD

VICE PRESIDENT PRICING, MARKET ACCESS & POLICY, EUROPA/CANADA/MEA; GENERAL MANAGER, CANADA, BENELUX, NORDICS AND PORTUGAL, ALNYLAM PHARMACEUTICALS, INC.

Start Me Up: How Can Europe’s Biotech Sector Combat the Coronavirus?

Cambridge, Massachusetts, United States